Metronidazole 600mg Tablet in PCD Pharma Franchise in Delhi

Metronidazole 600mg Tablet in Pharmaceutical Manufacturing Company in Indore

Metronidazole 600mg Tablet in General Medicine Pharma Franchise in Nagpur

Metronidazole 600mg Tablet in Pharma Distributors & Suppliers in Surat

Metronidazole 600mg Tablet in Pharma Export Company in Chennai
Metronidazole 600mg Tablet in Pharma Franchise Opportunity in Chandigarh

Home/Products /metronidazole-er-600-mg-tablet

About the Product

Description


Methafly 600 Tablet contains Metronidazole 600 mg, a powerful nitroimidazole-class antimicrobial agent used to treat a variety of anaerobic bacterial and protozoal infections. It works by entering the cells of anaerobic organisms and disrupting their DNA synthesis, leading to cell death. This bactericidal and antiprotozoal action makes it highly effective in managing infections in low-oxygen environments such as the gastrointestinal tract, pelvis, and oral cavity. The higher strength of 600 mg is typically used in moderate to severe infections or when a higher systemic concentration is required. It is commonly employed in the treatment of pelvic infections, amoebiasis, bacterial vaginosis, dental abscesses, and as part of combination regimens in surgical prophylaxis and Helicobacter pylori eradication therapy. Metofoli 600 Tablet offers an enhanced dosing option for clinicians aiming for a more aggressive or prolonged antimicrobial effect in serious infections.

Common side effects may include nausea, a metallic or bitter taste, headache, dry mouth, and gastrointestinal discomfort. Some individuals may experience dizziness, dark urine, vomiting, or loss of appetite. Rare but serious adverse effects include peripheral neuropathy (numbness or tingling in hands/feet), seizures, and allergic skin reactions. Long-term use should be closely monitored due to the risk of hematologic toxicity and neurological effects.

Methafly 600 Tablet is indicated for the treatment of serious anaerobic bacterial infections and protozoal infections, including amoebiasis (intestinal and hepatic), giardiasis, trichomoniasis, bacterial vaginosis, dental infections, pelvic inflammatory disease, intra-abdominal infections, and pseudomembranous colitis. It is also used in surgical prophylaxis and as adjunct therapy in combination with other antibiotics for mixed infections and H. pylori-related ulcers.

Methafly 600 Tablet must be used under the supervision of a qualified healthcare provider. It is essential not to consume alcohol during the course of therapy and for at least 48 hours after completing the dose, as it may lead to a disulfiram-like reaction characterized by nausea, flushing, and rapid heartbeat. Caution is advised in patients with liver impairment, seizure disorders, or blood disorders. Pregnant or breastfeeding women should use this medication only if clearly needed and prescribed by a physician. Complete the full course of treatment as advised to avoid resistance or recurrence of infection. Avoid unnecessary use and follow proper dosing schedules to ensure effectiveness.

Store Methafly 600 Tablet at a temperature below 30°C, protected from light, moisture, and excessive heat. Keep the tablets in their original packaging and out of reach of children. Do not use after the expiry date mentioned on the label.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Metronidazole 600 mg Tablets in the PCD pharma franchise market?

Metronidazole Tablets have strong demand in the anti-infective and gastroenterology segment, making them a reliable product for pharma distributors, wholesalers, and franchise partners. It is widely used for anaerobic bacterial infections, dental infections, gastrointestinal infections, and protozoal diseases, ensuring consistent prescription-driven demand.

Why should medical distributors include Metronidazole 600 mg Tablets in their product range?

Medical distributors and agencies benefit from the high clinical usage in infections and dental/GI practice. Effective against anaerobic bacterial and protozoal infections Commonly prescribed for dental infections, abdominal infections, and pelvic infections Widely used by general physicians, surgeons, and dentists Important in gastrointestinal infection management (e.g., amoebiasis, giardiasis) Strong hospital and retail prescription demand Frequently used as part of combination antibiotic therapy This makes it a fast-moving and essential anti-infective product.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Metronidazole 600 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and franchise partners benefit from steady infection-related prescription demand, strong hospital and dental clinic usage, repeat prescription cycles in GI infections, and stable year-round sales in the anti-infective segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete anti-infective product portfolio access to build a strong presence in the infection treatment market.